Prednisone Treatment Regimen for Minimal Change Disease

Initial Treatment Dosing

The Kidney International guideline recommends that prednisone should be given at a daily single dose of 1 mg/kg (maximum 80 mg) for a minimum of 4 weeks if complete remission is achieved, and tapered slowly over a total period of up to 6 months after achieving remission 1, 2
The initial high dose should be maintained for a minimum period of 4 weeks if complete remission is achieved, according to the Kidney International guideline 1
If complete remission is not achieved within 4 weeks, the high dose can be continued for a maximum period of 16 weeks, as recommended by the Kidney International guideline 1, 2

After achieving remission, prednisone should be tapered slowly over a total period of up to 6 months, as recommended by the Kidney International and American Journal of Kidney Diseases guidelines 1, 2, 3
A structured tapering approach helps prevent rebound symptoms and minimizes the risk of adrenal insufficiency, although the strength of evidence for this is not provided 4

For infrequent relapses, the same initial dose and duration of corticosteroids should be used as for the first episode, according to the Kidney International and American Journal of Kidney Diseases guidelines 1, 3
For patients with frequent relapses, daily prednisone should be given until remission (at least 3 days), followed by alternate-day prednisone for at least 3 months, as recommended by the Kidney International guideline 6

For patients with relative contraindications or intolerance to high-dose corticosteroids, oral cyclophosphamide or calcineurin inhibitors should be considered, according to the Kidney International and American Journal of Kidney Diseases guidelines 1, 3
Acute kidney injury in the setting of newly diagnosed minimal change disease should be treated with renal replacement therapy as indicated, along with corticosteroids as for a first episode, as recommended by the American Journal of Kidney Diseases guideline 3
For the initial episode of nephrotic syndrome associated with minimal change disease, statins are not recommended to treat hyperlipidemia, and ACE inhibitors or ARBs are not recommended in normotensive patients to lower proteinuria, according to the Kidney International and American Journal of Kidney Diseases guidelines 1, 3

Monitor for steroid-related side effects during treatment and tapering, although the strength of evidence for this is not provided 5
If symptoms recur during tapering, return to the pre-relapse dose and decrease more gradually (within 4-8 weeks) to the dose at which the relapse occurred, as recommended by the Praxis Medical Insights guideline, but the Kidney International guideline is preferred 5

Prolonged high-dose corticosteroid therapy without considering steroid-sparing agents in patients with frequent relapses or steroid dependence should be avoided, according to the American Journal of Kidney Diseases guideline 3